Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04055532

Biomarkers in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS) Clinical Trial

Official title:
Biomarkers in Neurodegenerative Diseases

Clinical Trial Summary

The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Alzheimer Disease
  • Alzheimer Disease (AD)
  • Amnesia
  • Amyotrophic Lateral Sclerosis
  • Amyotrophic Lateral Sclerosis (ALS)
  • Cognitive Dysfunction
  • Dementia
  • Dementia With Lewy Bodies (DLB)
  • Epilepsy, Temporal Lobe
  • Frontotemporal Lobar Degeneration
  • Frontotemporal Lobar Degeneration (FTLD)
  • HIV Associated Neurocognitive Disorder (HAND)
  • Lewy Body Disease
  • Mild Cognitive Impairment (MCI)
  • Motor Neuron Disease
  • Neurocognitive Disorders
  • Neurodegenerative Diseases
  • Parkinson Disease
  • Parkinsons Disease With Dementia (PDD)
  • Primary Lateral Sclerosis (PLS)
  • Sclerosis
  • Spinocerebellar Ataxias
  • Spinocerebellar Ataxias (SCA)
  • Spinocerebellar Degenerations
  • Temporal Lobe Epilepsy (TLE)
  • Transient Epileptic Amnesia (TEA)
Clinical Trial Details
NCT number NCT04055532
Study type Observational [Patient Registry]
Source University of Minnesota
Contact
Status Withdrawn
Phase
Start date October 1, 2019
Completion date October 1, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT02365922 - Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Completed NCT01699451 - DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida
Completed NCT04577404 - Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) Phase 3
Terminated NCT03580616 - Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT01884571 - Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Completed NCT00244244 - A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS Phase 2
Active, not recruiting NCT00420719 - Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS) N/A
Completed NCT02936635 - A Study for Patients Who Completed VITALITY-ALS (CY 4031) Phase 3
Completed NCT03645031 - Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease N/A
Completed NCT01786603 - Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Completed NCT02559869 - Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
Completed NCT01592552 - A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
Completed NCT00403104 - Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT02424669 - Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients N/A
Completed NCT02017912 - Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS Phase 2
Completed NCT01366027 - PRISM Registry: Pseudobulbar Affect Registry Series N/A
Completed NCT00330681 - Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Phase 3
Completed NCT00876772 - Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS) Phase 2/Phase 3
Not yet recruiting NCT06351592 - First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) Phase 1